科研动态PubMed 摘要

慢性偏头痛的程序性干预:一项伞状综述的干预特异性证据图。

PubMed 学科轮询 · 2026-10-12

完整摘要 · 中文译文

目的:综合并梳理针对慢性偏头痛(CM)程序性干预措施的疗效、临床相关性和安全性的干预特异性证据。方法:我们按照PRISMA 2020及伞状综述方法学指南,开展了一项在PROSPERO注册的伞状综述。纳入的系统综述评估了onabotulinumtoxinA、枕大神经阻滞(GONB)、其他周围神经阻滞及经皮操作、针灸、植入式枕神经刺激(ONS)或手术干预。关于在持续onabotulinumtoxinA治疗基础上加用CGRP靶向单克隆抗体治疗的证据,作为辅助药物治疗的背景证据单独保留,未归类为程序性干预。方法学质量采用系统综述方法学质量评估工具2(AMSTAR 2)评估,证据确定性采用推荐分级的评估、制定与评价(GRADE)评估,原始研究重叠情况采用校正覆盖面积(CCA)评估。证据按干预措施、结局、对照和随访期分别综合。不同系统综述的合并估计值未进行统计学合并,临床异质性证据采用叙述性总结。结果:共纳入17篇综述,其中12篇至少包含一项荟萃分析。各干预措施的证据强度和成熟度差异显著。OnabotulinumtoxinA拥有最成熟的证据基础,在CM预防中的作用最为明确。对于GONB,低- 来自临床可比随机试验的确定性证据提示,头痛天数和头痛严重程度可能出现短期减少,但持续获益仍不确定。A型肉毒毒素联合降钙素基因相关肽(CGRP)单克隆抗体治疗的证据主要来自非对照观察性队列,因此应视为初步证据。植入式枕神经刺激(ONS)在部分难治性慢性偏头痛(CM)患者中显示出可能获益,但证据受研究数量少、不精确、结局异质性以及装置或操作相关风险的限制。针灸、其他外周神经阻滞、经皮操作和手术干预的证据受临床异质性、间接性、非对照研究设计或对CM特定适用性不确定的限制。不同干预类别的治疗相关不良事件(TRAEs)特征差异显著,因此未跨操作进行合并。大多数干预-结局证据被评为低或极低确定性。 结论:CM的操作性干预不应被解释为同质的治疗类别。A型肉毒毒素拥有最成熟的证据支持和既定的临床定位,而大枕神经阻滞(GONB)可能提供短期、方案特异性的获益,确定性低。其他操作的证据仍为初步、异质性或仅限于特定患者人群。因此,临床解读和治疗选择应针对具体干预和具体患者。未来研究应优先考虑标准化诊断标准、治 治疗方案、对照措施、具有临床意义的结局、治疗相关不良事件(TRAEs)报告以及更长期的随访。系统评价注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420261415558,注册号:CRD420261415558。

完整摘要 · 英文原文

OBJECTIVE: To synthesize and map intervention-specific evidence on the efficacy, clinical relevance, and safety of procedural interventions for chronic migraine (CM). METHODS: We conducted a PROSPERO-registered umbrella review in accordance with PRISMA 2020 and methodological guidance for umbrella reviews. Eligible systematic reviews evaluated onabotulinumtoxinA, greater occipital nerve block (GONB), other peripheral nerve blocks and percutaneous procedures, acupuncture, implanted occipital nerve stimulation (ONS), or surgical interventions. Evidence concerning the addition of CGRP-targeted monoclonal antibody therapy to ongoing onabotulinumtoxinA treatment was retained separately as contextual evidence on adjunctive pharmacotherapy and was not classified as a procedural intervention. Methodological quality was assessed using A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2), certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE), and primary-study overlap using the corrected covered area (CCA). Evidence was synthesized separately by intervention, outcome, comparator, and follow-up period. Pooled estimates from different systematic reviews were not statistically combined, and clinically heterogeneous evidence was summarized narratively. RESULTS: Seventeen reviews were included, of which 12 contained at least one meta-analysis. The strength and maturity of evidence varied substantially across interventions. OnabotulinumtoxinA had the most established evidence base and the clearest role in CM prevention. For GONB, low-certainty evidence from clinically comparable randomized trials suggested a possible short-term reduction in headache day and headache severity, although sustained benefit remains uncertain. Evidence for combined onabotulinumtoxinA-CGRP monoclonal antibody therapy was derived predominantly from uncontrolled observational cohorts and should therefore be considered preliminary. Implanted ONS showed possible benefit in selected patients with refractory CM, but evidence was limited by small study numbers, imprecision, heterogeneous outcomes, and device- or procedure-related risks. Evidence for acupuncture, other peripheral nerve blocks, percutaneous procedures, and surgical interventions was limited by clinical heterogeneity, indirectness, uncontrolled study designs, or uncertain applicability specifically to CM. TRAEs profiles differed substantially among intervention categories and were therefore not pooled across procedures. Most intervention-outcome evidence was rated as low or very low certainty. CONCLUSIONS: Procedural interventions for CM should not be interpreted as a homogeneous therapeutic class. OnabotulinumtoxinA is supported by the most mature evidence and established clinical positioning, whereas GONB may provide a short-term, protocol-specific benefit with low certainty. Evidence for other procedures remains preliminary, heterogeneous, or restricted to selected patient populations. Clinical interpretation and treatment selection should therefore be intervention-specific and patient-specific. Future research should prioritize standardized diagnostic criteria, treatment protocols, comparators, clinically meaningful outcomes, TRAEs reporting, and longer-term follow-up. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261415558, identifier: CRD420261415558.

English
Procedural interventions for chronic migraine: an umbrella review intervention-specific evidence map.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界